Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERDICT: Reduced Dose DOAs in Renally Impaired VTE
NCT02664155Phase 3Terminated
- Sponsor
- CHU Saint-Etienne
- Start
- Oct 2016
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of apixaban, rivaroxaban in venous thromboembolism (VTE), sponsored by CHU Saint-Etienne. Started Oct 2016; status: terminated.
02
Drugs
apixabanrivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02664155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02664155.